Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	XL147	1	72	flat	flat	BT20 pilaralisib 0 1 72	8	2.128	Inf	0.815	0.048	0.0	0.815	0.01	0.411	0.205	0.939	Inf	0.813	0.95	0.0	0.813	0.01	0.383	0.234	0.937
BT-20	Trametinib	3	72	sigmoid	sigmoid	BT20 trametinib 0 3 72	8	2.539	Inf	0.64	0.208	0.104	0.541	0.392	0.967	3.69e-05	NA	Inf	0.604	0.761	0.0656	0.513	0.391	0.964	4.56e-05	NA
BT-20	Everolimus	1	72	flat	flat	BT20 everolimus 0 1 72	8	2.002	Inf	0.546	0.403	0.0	0.546	0.01	-0.000401	1.0	0.595	Inf	0.597	0.638	0.0	0.597	0.01	-0.327	1.0	0.636
BT-20	TGX221	3	72	flat	flat	BT20 TGX-221 0 3 72	8	2.469	Inf	1.01	0.0147	0.0	1.01	0.01	-0.0563	1.0	0.982	Inf	1.01	0.983	0.0	1.01	0.01	-0.0552	1.0	0.979
BT-20	TGX221	2	72	flat	flat	BT20 TGX-221 0 2 72	8	1.656	Inf	1.0	0.0477	0.0	1.0	0.01	-0.101	1.0	0.946	Inf	1.0	0.961	0.0	1.0	0.01	-0.101	1.0	0.956
BT-20	KIN001-244	3	72	flat	flat	BT20 KIN001-244 0 3 72	8	2.608	Inf	0.841	0.062	0.0	0.841	0.01	0.489	0.133	0.935	Inf	0.805	0.922	0.0	0.805	0.01	0.475	0.145	0.919
BT-20	AS605240	1	72	sigmoid	sigmoid	BT20 AS-605240 0 1 72	8	2.142	Inf	0.817	0.0993	3.91	0.634	0.244	0.861	0.00271	NA	Inf	0.814	0.897	3.87	0.629	0.237	0.854	0.00311	NA
BT-20	Sirolimus	3	72	flat	flat	BT20 rapamycin 0 3 72	8	2.661	Inf	0.54	0.46	0.0	0.54	0.01	NA	NA	0.54	Inf	0.499	0.499	0.0	0.499	0.01	NA	NA	0.499
BT-20	Sirolimus	2	72	flat	flat	BT20 rapamycin 0 2 72	8	1.952	Inf	0.421	0.579	0.0	0.421	0.01	NA	NA	0.421	Inf	0.513	0.513	0.0	0.513	0.01	NA	NA	0.513
BT-20	Everolimus	2	72	flat	flat	BT20 everolimus 0 2 72	8	1.785	Inf	0.426	0.574	0.0	0.426	0.01	NA	NA	0.426	Inf	0.547	0.547	0.0	0.547	0.01	NA	NA	0.547
BT-20	AS605240	3	72	sigmoid	sigmoid	BT20 AS-605240 0 3 72	8	2.607	Inf	0.845	0.0823	4.13	0.662	0.292	0.729	0.0199	NA	Inf	0.81	0.897	3.97	0.589	0.284	0.712	0.0239	NA
BT-20	TGX221	1	72	flat	flat	BT20 TGX-221 0 1 72	8	1.988	Inf	1.02	-0.00357	0.0	1.02	0.01	-0.00762	1.0	1.0	Inf	1.02	1.0	0.0	1.02	0.01	-0.00881	1.0	1.0
BT-20	MK2206	1	72	sigmoid	sigmoid	BT20 MK-2206 0 1 72	8	2.089	Inf	0.732	0.102	4.16	0.529	0.345	0.671	0.0357	NA	Inf	0.741	0.898	4.14	0.538	0.337	0.676	0.034	NA
BT-20	Everolimus	3	72	flat	flat	BT20 everolimus 0 3 72	8	2.422	Inf	0.475	0.456	0.0	0.475	0.01	0.602	0.0632	0.543	Inf	0.478	0.534	0.0	0.478	0.01	0.561	0.0844	0.534
BT-20	BX-912	1	72	flat	flat	BT20 BX-912 0 1 72	8	2.193	Inf	0.858	0.0928	0.0	0.858	0.01	0.25	0.422	0.903	Inf	0.851	0.901	0.0	0.851	0.01	0.243	0.433	0.897
BT-20	BX-912	2	72	flat	flat	BT20 BX-912 0 2 72	8	1.873	Inf	0.683	0.213	0.0	0.683	0.01	0.118	0.686	0.777	Inf	0.724	0.81	0.0	0.724	0.01	0.111	0.702	0.802
BT-20	BX-912	3	72	flat	flat	BT20 BX-912 0 3 72	8	2.619	Inf	0.904	0.0795	0.0	0.904	0.01	0.000173	0.999	0.918	Inf	0.879	0.9	0.0	0.879	0.01	0.00619	0.982	0.896
BT-20	KIN001-244	1	72	flat	flat	BT20 KIN001-244 0 1 72	8	2.125	Inf	0.911	0.0401	0.0	0.911	0.01	-0.00641	1.0	0.957	Inf	0.908	0.958	0.0	0.908	0.01	-0.00745	1.0	0.955
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.0	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.0	0.6	0.01	-13.0	1.0	0.6
BT-20	KIN001-244	2	72	sigmoid	sigmoid	BT20 KIN001-244 0 2 72	8	1.742	Inf	0.85	0.0644	4.47	0.713	0.316	0.721	0.0218	NA	Inf	0.873	0.945	4.51	0.757	0.309	0.715	0.0231	NA
BT-20	CAL-101	1	72	flat	flat	BT20 idelalisib 0 1 72	8	2.112	Inf	0.869	0.0546	0.0	0.869	0.01	0.0807	0.777	0.938	Inf	0.867	0.943	0.0	0.867	0.01	0.0778	0.784	0.936
BT-20	CAL-101	2	72	flat	flat	BT20 idelalisib 0 2 72	8	1.768	Inf	0.818	0.0943	0.0	0.818	0.01	0.226	0.463	0.898	Inf	0.845	0.918	0.0	0.845	0.01	0.222	0.471	0.912
BT-20	CAL-101	3	72	flat	flat	BT20 idelalisib 0 3 72	8	2.589	Inf	0.916	0.0535	0.0	0.916	0.01	0.0547	0.845	0.944	Inf	0.894	0.932	0.0	0.894	0.01	0.0506	0.856	0.929
BT-20	XL147	3	72	flat	flat	BT20 pilaralisib 0 3 72	8	2.647	Inf	0.755	0.102	0.0	0.755	0.01	0.0679	0.81	0.885	Inf	0.708	0.871	0.0	0.708	0.01	0.0505	0.856	0.857
BT-20	XL147	2	72	flat	flat	BT20 pilaralisib 0 2 72	8	1.784	Inf	0.759	0.073	0.0	0.759	0.01	-0.0058	1.0	0.907	Inf	0.796	0.937	0.0	0.796	0.01	-0.00637	1.0	0.92

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)